Polymyxin B Sulphate

Polymyxin B sulfate is currently the first-choice drug for treating infections caused by multidrug-resistant Pseudomonas aeruginosa and other Gram-negative bacteria. It has a low resistance rate and does not produce cross-resistance with other classes of antibiotics or antimicrobial agents. It is an urgently needed superantibiotic for critically ill patients in China and serves as the "last line of defense" against "superbug" infections. Fokam Pharmaceutical's Polymyxin B sulfate has a CDE registration status of "I".